Literature DB >> 19938743

Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs.

Chaveewan Ratanajamit1, Peerasak Kaewpibal, Suwanna Setthawacharavanich, Damrongsak Faroongsarng.   

Abstract

OBJECTIVE: To compare the proportions of appropriate TDM utilization regarding the indication, sampling time, and application of the measured drug levels of antiepileptic drugs (AEDs) between the pre-intervention period and pharmacist intervention period. MATERIAL AND
METHOD: The baseline evaluation and pharmacist intervention study of TDM use for phenytoin, carbamazepine, or valproic acid were conducted at a medical teaching hospital in Southern Thailand. TDM requests, interpretation and dosage adjustment recommendations were mainly responsible by residents. In the intervention period, each of the three-step TDM process was assessed by the pharmacist for appropriateness and a suggestion provided if necessary prior to a final recommendation made by the resident. The criteria for appropriateness of TDM for AEDs were developed and validated by two neurologists. The present study included 44 TDM tests (22 patients) during the baseline period and 43 tests (27 patients) during the intervention period. The proportions of appropriate TDM utilization between the two periods were compared using Chi-square test.
RESULTS: In the baseline period, proportions of appropriately performed TDM were: indication (63.6%), sampling time (47.7%), and application of drug levels (63.6%). Pharmacist intervention significantly increased the proportions of appropriate indication (97.7%, p = 0.001), sampling time (79.1, p = 0.0023), and applications (83.7%, p = 0.0293). There were 12 tests (27.3%) and 29 tests (67.4%) (p = 0.0001) during the baseline and the intervention period, respectively, that met all 3 criteria of appropriate TDM use. Sixteen requests without indication found in the baseline period was reduced to one in the intervention period, and thus reduced the unnecessary cost by 90%. Of 59 steady-state drug levels, 34 (57.6%, p = 0.0005) significantly correlated with clinical responses.
CONCLUSION: Pharmacist intervention significantly improved appropriateness of TDM use, and substantially reduced unnecessary costs. Using a screening checklist including the indication, sampling time and data needed for proper interpretation of the results can help improve the appropriateness of TDM utilization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19938743

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  11 in total

1.  Clinical pharmacokinetics: perceptions of hospital pharmacists in Qatar about how it was taught and how it is applied.

Authors:  Nadir Kheir; Ahmed Awaisu; Hoda Gad; Shereen Elazzazy; Farah Jibril; Mawadda Gajam
Journal:  Int J Clin Pharm       Date:  2015-09-04

2.  A survey of therapeutic drug monitoring services in Malaysia.

Authors:  Ab Fatah Ab Rahman; Hisham Elhag Ahmed Abdelrahim; Mohamed Izham Mohamed Ibrahim
Journal:  Saudi Pharm J       Date:  2012-01-14       Impact factor: 4.330

3.  Epidemiology and cost analysis of pharmacist interventions at Ghent University Hospital.

Authors:  Barbara O M Claus; Fien M R Vandeputte; Hugo Robays
Journal:  Int J Clin Pharm       Date:  2012-07-19

Review 4.  A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions.

Authors:  Rachel A Elliott; Koen Putman; James Davies; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

Review 5.  Emerging roles for pharmacists in clinical implementation of pharmacogenomics.

Authors:  Aniwaa Owusu-Obeng; Kristin W Weitzel; Randy C Hatton; Benjamin J Staley; Jennifer Ashton; Rhonda M Cooper-Dehoff; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2014-09-15       Impact factor: 4.705

6.  Therapeutic drug monitoring in epilepsy clinic: a multi-disciplinary approach.

Authors:  Sunee Lertsinudom; Aporanee Chaiyakum; Supinya Tuntapakul; Kittisak Sawanyawisuth; Siriporn Tiamkao; Somsak Tiamkao
Journal:  Neurol Int       Date:  2014-12-16

7.  Prevalence of Therapeutic Drug Monitoring for Lithium and the Impact of Regulatory Warnings: Analysis Using Japanese Claims Database.

Authors:  Nobuhiro Ooba; Daisuke Tsutsumi; Naoko Kobayashi; Shinji Hidaka; Hiroyuki Hayashi; Taku Obara; Michihiro Satoh; Kiyoshi Kubota; Noriyasu Fukuoka
Journal:  Ther Drug Monit       Date:  2018-04       Impact factor: 3.681

8.  Measuring the appropriateness of carbamazepine and valproic acid prescribing and utilization using a newly implemented online system in the Tabuk Region of Saudi Arabia.

Authors:  Reem S Al-Balawi; Mohammed A Alshehri; Abdullah S Alatawi; Abdullah M Al Shehri; Manal A Alshehry; Mohammed M H Al-Gayyar
Journal:  Saudi Pharm J       Date:  2020-06-20       Impact factor: 4.330

Review 9.  Pharmacogenomics In Pharmacy Practice: Current Perspectives.

Authors:  Hazem Elewa; Ahmed Awaisu
Journal:  Integr Pharm Res Pract       Date:  2019-11-08

10.  Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman.

Authors:  Mohammed Al Za'abi; Juhina Al Muqbali; Khalid Al-Waili
Journal:  Saudi Pharm J       Date:  2014-11-24       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.